Lionheart Health Files Patent for Bioelectric-Enhanced Klotho Nanoflowers Targeting Aging Reversal

Lionheart Health, Inc. announced the filing of a non-provisional U.S. patent covering its Bioelectric-Enhanced Klotho Nanoflowers platform for aging reversal and healthspan extension. The patent protects a therapeutic system that integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging. This invention combines several proprietary Lionheart technologies, including BodStim™, BrainBand™, and advanced Klotho-based peptides and gene-expression tools.

The platform centers on engineered "nanoflowers"—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein shown to improve brain, kidney, cardiovascular, and metabolic health. These nanoflowers restore mitochondrial function by enhancing ATP production and reducing oxidative stress, deliver targeted bioactive agents including peptides and CRISPRa activators, act as nanozyme catalysts that reduce ROS, and enhance regenerative signaling when activated by precise bioelectric patterns. The nanoflowers are engineered to respond to Lionheart's proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance.

Howard J. Leonhardt, Founder and CEO of Lionheart Health, stated that this invention represents the convergence of three powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation. The goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably. The nanoflowers are specifically engineered to respond to bioelectric fields, with signals increasing cellular uptake, intracellular transport, and activation of the nanoflower's catalytic and genetic payloads. Thus, nanoflowers require bioelectric activation for optimal performance, and the bioelectric component is designed to operate in the presence of the nanoflowers.

Bioelectric stimulation is applied to open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release. Klotho expression increases due to nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways. Neither nanoflowers nor bioelectric stimulation alone can produce the full Klotho-enhancing effect, demonstrating a combined therapeutic benefit mechanism. The system is designed for system-wide healthspan improvement, including mitochondrial biogenesis, reduction of cellular senescence, and stabilization of biological age.

Klotho is recognized as a promising longevity molecule, with decreased levels associated with accelerated aging, cognitive decline, and other health issues. Increasing Klotho expression has shown benefits in preclinical models of brain aging, muscle repair, and metabolic health. Lionheart's platform advances this science by enabling targeted Klotho delivery and activation inside mitochondrial and cellular compartments responsible for aging. Dr. Leslie Miller, Chief Medical Officer, noted that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity.

The patent filing adds to Lionheart Health's intellectual property portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration technologies, and Klotho-based gene therapy. Optional components include closed-loop adaptive control, where sensors measure mitochondrial markers to adapt stimulation patterns, and multi-modal integration combining nanoflowers with bioelectric, peptides, and regenerative support. Therapy will be delivered in iterative sessions at baseline, 3-month, 6-month, and 12-month intervals. Lionheart Health is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program.